METHOD FOR THE SYNCHRONOUS LYMPHATIC METASTASIS PREDICTION IN THE PATIENTS WITH NON-SMALL CELL LUNG CANCER FOLLOWING THE NEOADJUVANT CHEMOTHERAPY Russian patent published in 2021 - IPC G01N33/50 G01N33/49 

FIELD: medicine.

SUBSTANCE: invention relates to medicine and concerns a method for predicting synchronous lymphatic metastasis in non-small-cell lung cancer patients following neoadjuvant chemotherapy. Method comprises evaluating leukocyte count, thrombocyte count, C-reactive protein concentration. Further, the probability of lymphatic metastasis is calculated from the value of regression equation Y by formula: Y = -64.8 + 37.5 X1 + 4.2X2 - 30.4 X3, where: -64.8 is free member regression coefficient value; X1 - blood leukocyte level, X1 = 1 with blood leukocyte level less than 4×10⁹/l, X1 = 2 with blood leukocyte level (4-7)×10⁹/l, X1 = 3 with blood leukocyte level (7-10)×10⁹/l, X1 = 4 with blood leukocyte level more than 10×10⁹/l; X2 is platelet blood level, X2 = 1 with platelet blood level less than 100×10⁹/l, X2 = 2 with platelet level in blood (100-200)×10⁹/l, X2 = 3 with platelet level in blood (200-300)×10⁹/l, X2 = 4 with blood platelet level more than 300×10⁹/l; X3 is concentration of CRP in blood, X3 = 1 with blood CRP concentration of 5 mg/l, X3 = 2 concentration of CRP in blood more than 5 mg/l. Probability of the presence of lymphogenic metastases P is determined by the formula: P = e^Y/(1 + e^Y), where e = 2.72. At probability P≥50% define a high risk of having lymphogenic metastases, while a probability of P <50% is a low risk of having lymphogenic metastases.

EFFECT: using the method enables high-accuracy determination of the postoperative therapeutic approach.

1 cl, 2 ex